TransCode Therapeutics Earlier Issued Open Letter To Shareholders; Asks Shareholders To Give Co Authorization To Effect A Reverse Stock Split, As A Last Resort Incase The Nasdaq Panel Hearing Recommends Shares To Be Delisted
TransCode Therapeutics Earlier Issued Open Letter To Shareholders; Asks Shareholders To Give Co Authorization To Effect A Reverse Stock Split, As A Last Resort Incase The Nasdaq Panel Hearing Recommends Shares To Be Delisted
The Board and Management of TransCode Therapeutics (NASDAQ:RNAZ) today issued the following open letter to shareholders of the Company:
TransCode Therapeutics（納斯達克股票代碼：RNAZ）的董事會和管理層今天向公司股東發表了以下公開信：
The reason for requesting the authority to do the reverse split is that, as a last resort, we can inform the Panel that shareholders have authorized a reverse split. There is also no assurance that the authorization (alone or in combination with other reasons we will provide the Panel) will result in our stock not being delisted, but the company and its advisors believe this is our best chance.
請求授權進行反向拆分的原因是，作爲最後的手段，我們可以告知小組，股東已經批准了反向拆分。也無法保證授權（單獨或結合我們將向小組提供的其他理由）將導致我們的股票不被退市，但該公司及其顧問認爲這是我們的最佳機會。
We believe having our stock continue to be listed on The Nasdaq Capital Market will be valuable in a number of ways in the future.
我們認爲，讓我們的股票繼續在納斯達克資本市場上市，將來在許多方面都具有價值。
We hope to not have to effect a reverse split, but we also believe that our shareholders are best served by doing everything we can to continue to be Nasdaq-listed.
我們希望不必進行反向拆分，但我們也認爲，盡一切努力繼續在納斯達克上市，對我們的股東最有利。
譯文內容由第三人軟體翻譯。